Barclays reiterated their underweight rating on shares of Hikma Pharmaceuticals (LON:HIK) in a research note published on Friday. The brokerage currently has a GBX 1,400 ($18.06) price target on the stock.
Several other analysts also recently commented on the stock. JPMorgan Chase & Co. reissued a neutral rating and set a GBX 1,050 ($13.54) price objective on shares of Hikma Pharmaceuticals in a research report on Tuesday, August 21st. Citigroup increased their price objective on shares of Hikma Pharmaceuticals from GBX 1,675 ($21.61) to GBX 2,100 ($27.09) and gave the company a buy rating in a research report on Monday, August 20th. Peel Hunt raised shares of Hikma Pharmaceuticals to an add rating and increased their price objective for the company from GBX 1,160 ($14.96) to GBX 1,950 ($25.15) in a research report on Thursday, August 16th. Numis Securities reissued a hold rating on shares of Hikma Pharmaceuticals in a research report on Wednesday, August 15th. Finally, Jefferies Financial Group reissued a hold rating and set a GBX 997 ($12.86) price objective on shares of Hikma Pharmaceuticals in a research report on Friday, May 18th. Two investment analysts have rated the stock with a sell rating, six have issued a hold rating and one has given a buy rating to the stock. The company has a consensus rating of Hold and a consensus price target of GBX 1,330.22 ($17.16).
Shares of HIK stock opened at GBX 1,906 ($24.59) on Friday. Hikma Pharmaceuticals has a one year low of GBX 814.20 ($10.50) and a one year high of GBX 2,346 ($30.26).
In related news, insider Sigurdur Olafsson purchased 20,000 shares of the company’s stock in a transaction dated Wednesday, May 30th. The shares were purchased at an average price of GBX 1,309 ($16.89) per share, with a total value of £261,800 ($337,719.30).
About Hikma Pharmaceuticals
Hikma Pharmaceuticals PLC develops, manufactures, and markets a range of generic, branded, and in-licensed pharmaceutical products in solid, semi-solid, liquid, and injectable final dosage forms. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment manufactures, markets, and sells generic injectable products for therapeutic categories, including anti-infective, anaesthetic, central nervous system (CNS), oncology, and pain management, as well as controlled substances and cardiovascular products.
Further Reading: Market Capitalization
Receive News & Ratings for Hikma Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hikma Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.